Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Nearly 11 million people have gotten Pfizer's COVID shot in the same time, according to IQVIA data shared by an analyst. Moderna confirmed that CEO Stephane Bancel will vacate his additional role ...

FTC sues drug middlemen for allegedly inflating insulin prices Pfizer says drug for deadly cancer condition that causes ...

dosages of the Pfizer-BioNTech vaccine. Other vaccines (such as Moderna) were excluded from analyses. The final older (12-17 ...

Both the Moderna and Pfizer/BioNTech actions are being heard in a Delaware district court. The lawsuits contribute to an ongoing bun fight between various parties involved in mRNA vaccines ...

With US government supplies of Covid vaccines predicted to run out in the first quarter of 2023, it has been revealed that Pfizer/BioNTech ... At the time of writing, Moderna had not as yet ...

Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker ...